Phase 3 study for people with Kidney Cancer

Recruiting Phase 3

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 3
Sponsor Arcus Biosciences, Inc.
Registry number NCT07011719
Started 8 September 2025 Today 16 October 2026 Estimated completion 1 April 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Research Site Box Hill Australia Recruiting
Research Site Camperdown Australia Recruiting
Research Site Chermside Australia Recruiting
Research Site Elizabeth Vale Australia Recruiting
Research Site Frankston Australia Recruiting
Research Site Frenchs Forest Australia Recruiting
Research Site Heidelberg Australia Recruiting
Research Site Hobart Australia Recruiting
Research Site Kurralta Park Australia Recruiting
Research Site Macquarie Park Australia Recruiting
Research Site South Brisbane Australia Recruiting
Research Site St Albans Australia Recruiting
Research Site Subiaco Australia Recruiting
Research Site Westmead Australia Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years and over
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 720

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Unresectable and measurable locally advanced or metastatic renal cell carcinoma with a primary clear cell component.

* A Karnofsky Performance Status (KPS) score ≥ 80%

* At least 1 target lesion measurable by computed tomography/magnetic resonance imaging per RECIST 1.1, not within a field of prior radiation therapy.

* Adequate organ and marrow function, ≤ 1 week prior to randomization.

* Women of childbearing potential (WOCBP) must have a negative serum pregnancy test.

Exclusion Criteria:

* Received prior treatment with a HIF-2α inhibitor or cabozantinib.

* Other prior malignancy active within the previous year except for locally curable cancers that have been apparently cured.

* Ongoing clinically significant toxicities related to any prior anticancer treatment, or toxicities Grade ≥ 3 per National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0) regardless of relatedness to prior anticancer therapies.

* Uncontrolled or poorly controlled hypertension, defined as a sustained blood pressure \> 150 mmHg systolic or \> 90 mmHg diastolic despite optimal antihypertensive treatment.

* History of leptomeningeal disease or spinal cord compression.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Dates on the record

Started 8 September 2025
Estimated completion 1 April 2028
Registry last updated 29 September 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 29 September 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.